close

PDI, Inc. provides outsourced pharmaceutical sales and marketing services to biopharmaceutical and life sciences industries in the United States. It offers a range of sales support services, as well as marketing research, physician interaction, and medical education programs. The company's services offer customers a range of promotional options for the commercialization of their products throughout their lifecycles, from development through maturity. PDI focuses primarily on product detailing, which involves a sales representative meeting face-to-face with targeted physicians and other healthcare decision makers to provide a technical review of the product being promoted. It also offers a portfolio of expanded sales services, which include talent acquisition services, pulsing teams, and vacancy coverage services. In addition, the company provides performance sales team, as well as a shared sales team that provides a face-to-face selling resource to those customers who want an alternative to a dedicated team. PDI's marketing services include creation, designing, and implementation of promotional peer interactive programming through a number of different venues, including teleconferences, dinner meetings, Web casts, satellite, and other alternative media. These programs offer various services, including strategic design, tactical execution, technology support, audience recruitment, moderator services, and thought leader management. Further, the company provides pharmaceutical marketing research services, including studies to identify the impact business strategy, profile, positioning, message, execution, implementation, and post implementation for a product. Additionally, it develops and executes continuing medical education services funded by the biopharmaceutical, and medical device and diagnostics industries. PDI, Inc. was founded in 1988 and is headquartered in Saddle River, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	6.50
Volume	24298
Volume Avg	17618
52 Week High	9.56
52 Week Low	5.27
PE	N/A
PE (group average)	40
EPS Year	-0.82
EPS change Q/Q	-77.78%
EPS change Q/Q Yr ago	-66.67%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-420%
REV change Q/Q	3.13%
REV change Q/Q Yr ago	48.23%
EPS next Q est	0.03
EPS next Y est	0.38
Divident Annual	0.00
Dividend Yield	0%